ArticleActa pharmacologica Sinica2026
Enhanced substance P-NK1R signaling in the parabrachial-parasubthalamic pathway promotes hyperalgesia and affective aversion in neuropathic pain.
Article in Acta pharmacologica Sinica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic neuropathic pain is sustained by nerve injury-induced central sensitization and is characterized by both sensory and affective manifestations. However, its underlying neural circuit mechanisms remain to be fully elucidated. Here, we revealed that CaMKII-expressing neurons in the parasubthalamic nucleus (PSTN) were recruited and exhibited hyperactivity in a neuropathic pain mouse model, established via spared nerve injury of the sciatic nerve (SNI). Optogenetic and chemogenetic inhibition of PSTN CaMKII neurons alleviated hyperalgesia and induced conditioned place preference (CPP) in SNI mice, without altering pain thresholds in sham mice. Mechanistically, we demonstrated that PSTN neurons received monosynaptic glutamatergic inputs from tachykinin precursor 1 (Tac1)-expressing neurons in the lateral parabrachial nucleus (LPB), and were excited by glutamate and substance P (SP) co-released from this projection. Inhibition of the LPB-PSTN projection recapitulated the analgesic and CPP-inducing effects of direct inhibition of PSTN neurons in SNI mice. Notably, these therapeutic effects were mimicked by local administration of a neurokinin receptor 1 (NK1R) antagonist, but were reversed by intra-PSTN injection of SP. Together, this study not only establishes the involvement of the LPB-PSTN circuit and local NK1R in the pathophysiology of neuropathic pain but also demonstrates their promise as therapeutic targets.
Indexed as
Identifiers
42552466What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.